Rezulin (troglitazone) for Type II diabetes

    The FDA and the HPB are considering Rezulin (troglitazone) for Type II diabetes.

    Troglitazone will be the first drug in a new class.

    It helps reduce insulin underlying metabolic defect in most patients with Type II diabetes.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote